Latest news with #Minghui
Epoch Times
3 days ago
- Politics
- Epoch Times
After 22 Years on the Run for Broadcasting the Truth, Falun Gong Practitioner Dies in Exile
Wang Zhanhai, a Falun Gong practitioner from northern China, died on May 10, 2024, after 22 years of exile, according to news published this month by Wang was forced into hiding after participating in a covert broadcast that exposed the Chinese Communist Party's (CCP's) persecution of Falun Gong. In January 2001, the CCP Since the CCP's nationwide persecution of Falun Gong began in 1999, practitioners have risked imprisonment and death to counter the state's defamatory narrative. Their efforts include On Feb. 16, 2002, Wang and six other Falun Gong practitioners in Anshan City, Liaoning Province, tapped into the local cable network at 7 p.m. to air a documentary called ' This was one of the first television network interception efforts recorded by Minghui. Exposing the CCP Hoax The attempt to bring this information to the public came at a steep cost. Related Stories 5/5/2025 4/29/2025 Police located the group during the operation and opened fire, shooting practitioner Xu Zhaobin in the leg and face. Wang managed to escape, fled his hometown, and remained in hiding for the next 22 years. The other six were captured in the next several weeks. All received severe punishment. File photo: Zhang Li. Courtesy of Minghui Zhang Li, arrested on March 3, 2002, was interrogated and tortured in the First Detention Center of Anshan City. She died on Aug. 27 in the same year after being denied medical treatment despite being in critical condition. Witnesses described her body as 'scored with bloody knife wounds.' She was 40. The remaining five—Wei Zhiyi, Shen Hailong, Xu Zhaobin, Li Guihong, and He Xiaoqiu—were Wang's Fight for Justice In 2015, while still in hiding, Wang filed a criminal complaint against Jiang. He accused the former CCP leader of 'throwing hundreds of millions of kind-hearted people and their families into turmoil and devastating basic human conscience and the moral foundation essential for a stable and sustainable society.' Wang wrote that Falun Gong had improved his health and helped him become a better person. But once the persecution began, he endured constant harassment, including from local police, factory supervisors, and others. He was stalked, pressured to renounce his beliefs, fined, and forced to resign from his job. Wang said he and his fellow practitioners then decided to do something to raise the public awareness of the persecution. In addition to handing out flyers, they thought of a better way to let more people know about the truth: intercepting the local cable system. After the 2002 broadcast, he was listed as a fugitive. 'The police tapped my home phone, harassed my family, and even revoked my wife's small subsidy—leaving her and our child in deep financial trouble,' Wang wrote. 'They tried to bribe my friends to find me. During holidays, officers staked out my parents' house. Everyone in my family lived under unbearable pressure.' Unable to work or go out, Wang lived in constant fear. He couldn't care for his elderly parents or support his family, he said. He described the toll as 'unimaginable' in terms of physical, emotional, and financial stress. His health declined in the years that followed before his death last year. Due to China's tight censorship, his death was only confirmed and reported by Minghui on May 6, 2025. Wang Zhanhai. Courtesy of Minghui Speaking Out for All of Humanity Wang Zhiyuan, president and spokesperson of the World Organization to Investigate the Persecution of Falun Gong (WOIPFG), said Falun Gong practitioners risk their lives not just for their own sake, but 'for the people, the society, and the nation.' He told The Epoch Times on Thursday that practitioners outside China are also speaking out—not only on behalf of those suffering inside the country, but also 'to defend freedom and truth for all humanity.' Bypassing the Firewall Falun Gong—also known as Falun Dafa—is a spiritual discipline based on the principles of truthfulness, compassion, and forbearance. Introduced by Mr. Li Hongzhi in 1992, it grew rapidly due to its health and moral benefits, attracting at least 70 million followers by the late 1990s. Fearing Falun Gong's popularity, the CCP launched a sweeping nationwide suppression in 1999. State media and propaganda arms were mobilized to discredit the practice. Despite extreme surveillance, including the deployment of more than The 2022 documentary ' Promotional materials for the documentary "Eternal Spring" are on display at the Film Forum in New York, on Oct. 14, 2022. Chung I Ho/The Epoch Times Inspired by their counterparts in China, Falun Gong practitioners overseas helped develop anti-censorship tools such as FreeGate, UltraSurf, and Dynaweb. These tools bypass the regime's 'Golden Shield,' also known as the Great Firewall, which monitors and censors internet access in China. Author and China expert Ethan Gutmann praised the movement, More Support Needed Prominent Chinese dissident Yuan Hongbing, now based in Australia, called the CCP 'the most evil authoritarian regime in human history.' In an interview with The Epoch Times on Thursday, he warned that the spread of communist totalitarianism poses a threat to global civilization. 'For years, Falun Gong practitioners have carried out tireless and courageous truth-clarification efforts,' Yuan said. 'What they are doing is tearing through the CCP's ideological iron curtain, allowing free thought and ideals to flow into China like a spring breeze. This is an immensely meaningful movement to save the hearts and minds of the Chinese people.' He also pointed to a rise in the CCP's overseas suppression of Falun Gong, with the communist regime spreading false information and employing legal tactics to target the group. 'It's hate-driven persecution from a dictatorship,' he said, urging the international community to respond with strong countermeasures. On May 5, the U.S. House of Representatives passed the WOIPFG's Wang Zhiyuan expressed appreciation to the United States for passing the bill, and he called on Western democracies to stand by the U.S. in support of Falun Gong. 'We need real action—not just symbolic support or oral sanctions,' he said. 'Only concrete steps can stop the persecution and dismantle the CCP.' Luo Ya, Mary Hong, and Joan Delaney contributed to this report.
Yahoo
20-05-2025
- Business
- Yahoo
Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC
SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety and efficacy of an investigational combination therapy with MHB039A, a PD-1xVEGF bispecific antibody, and MHB036C, a TROP-2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC). MHB039A is a novel bispecific antibody targeting PD-1 and VEGF. It demonstrated full blocking activities against both PD-1 and VEGF with superior PD-1 activity compared to competitor antibodies. In a completed Phase Ⅰ dose-escalation study, MHB039A was well-tolerated at doses up to 30 mg/kg, with no DLTs observed and the MTD not reached. The safety profile was consistent with that of previously reported PD-1xVEGF bispecifics. Robust PD-1 receptor occupancy and VEGF biomarker responses were observed across all dose levels. Encouraging anti-tumor activity was noted in NSCLC patients who had progressed after prior PD-1 inhibitor and chemotherapy treatment. MHB036C is a novel antibody-drug conjugate targeting TROP-2, developed using Minghui's proprietary SuperTopoi™ ADC platform. In ongoing Phase 1/2 studies, MHB036C has been evaluated in 138 patients with advanced or metastatic solid tumors. The ADC has demonstrated a favorable safety profile, with no major hematologic adverse events and ILD. Promising anti-tumor activity has been observed in heavily pre-treated NSCLC and breast cancer patients. "We are excited to initiate this Phase Ⅱ trial investigating the combination therapy with MHB039A and MHB036C in advanced NSCLC," said Guoqing Cao, Ph.D., Chief Executive Officer of Minghui Pharmaceutical. "Emerging clinical data increasingly support the potential of combining ADCs with immuno-oncology (I/O) agents to achieve more robust and durable anti-tumor responses across multiple solid tumors. We believe these combinations will play a pivotal role in reshaping the standard-of-care treatment paradigms. Our PD-1xVEGF bispecific antibody offers a promising new backbone for I/O-based combination therapies." Dr. Cao added, "This trial underscores our strategic focus on developing ADCs and PD-1xVEGF bispecific combination therapies and establishes a strong foundation for extending this approach to other solid tumors, including breast cancer." About Minghui Pharmaceutical Minghui Pharmaceutical is a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address unmet medical needs in oncology and autoimmune diseases. With expertise in medical science and proprietary technology platforms, the company has built a diverse clinical-stage pipeline, including novel ADC programs and a PD-1xVEGF bispecific antibody. Minghui is committed to advancing breakthrough therapies that improve patient outcomes worldwide. For more information, please visit Forward-Looking Statements This press release provided by Minghui Pharmaceutical Inc. (the "Company") contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "predict," "should," "will," "would" or words of similar meaning. These statements are based on the Company's current beliefs and expectations and subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the statements herein. Risks and uncertainties include but not limited to: general industry conditions and competition; changes in economic and financial conditions of the Company's and the collaborators' businesses; the risk that clinical trials are discontinued or delayed for any reasons, including for efficacy, safety, enrollment, or manufacturing; the risk that success in early stage clinical trials may not be predictive of results in later stage trials or trials of other potential indications; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials; expectations for regulatory approvals; challenges to obtain, maintain and enforce patents and other intellectual property protection for the Company's product(s) and product candidate(s). These forward-looking statements speak only as of the date they are posted to this website, and the Company undertakes no obligation to update any forward-looking statements contained herein. View original content: SOURCE Minghui Pharmaceutical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
